{"title":"Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma.","authors":"N Zarghami, D Katsaros, H Yu, E P Diamandis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Creatine kinase BB isoenzyme (CK-BB) is overexpressed in many tumor tissues, including ovarian cancer. Using a highly sensitive and specific immunofluorometric method, CK-BB levels in 89 primary ovarian cancer cytosolic extracts have been measured and the associations between CK-BB and clinicopathological features of ovarian cancer have been studied. It was found that CK-BB levels are higher in endometrioid cell carcinomas. No clear association was established between CK-BB levels and patient age, menopausal status, clinical stage, histological grade or size of residual tumor. CK-BB was not associated significantly with either disease-free or overall survival of the patients. Based on these data, it was concluded that there is no prognostic value of CK-BB in ovarian cancer. Drugs that target CK-dependent energy metabolism of tumor cells may not be selective in ovarian cancer therapy.</p>","PeriodicalId":79379,"journal":{"name":"The Canadian journal of oncology","volume":"5 3","pages":"401-7"},"PeriodicalIF":0.0000,"publicationDate":"1995-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Canadian journal of oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Creatine kinase BB isoenzyme (CK-BB) is overexpressed in many tumor tissues, including ovarian cancer. Using a highly sensitive and specific immunofluorometric method, CK-BB levels in 89 primary ovarian cancer cytosolic extracts have been measured and the associations between CK-BB and clinicopathological features of ovarian cancer have been studied. It was found that CK-BB levels are higher in endometrioid cell carcinomas. No clear association was established between CK-BB levels and patient age, menopausal status, clinical stage, histological grade or size of residual tumor. CK-BB was not associated significantly with either disease-free or overall survival of the patients. Based on these data, it was concluded that there is no prognostic value of CK-BB in ovarian cancer. Drugs that target CK-dependent energy metabolism of tumor cells may not be selective in ovarian cancer therapy.